Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

NCT06820281 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: Tirzepatide 2.5mg weekly
DRUG: Placebo injection (normal saline)

Sponsor

Garvan Institute of Medical Research